


10572670

=> d 14
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 14
SAMPLE SEARCH INITIATED 14:45:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE



100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=>
Uploading C:\Documents and Settings\EBernhardt\My
Documents\Stnexp\Queries\10572670-2.str

10572670



```
chain nodes :
17 18 19 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 20 21 22 23 24 25
chain bonds :
1-14 8-17 11-27 17-21 17-18 17-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16 20-21 20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
1-14 8-17 11-12 11-16 12-13 13-14 14-15 15-16 17-21 17-18 17-19
exact bonds :
11-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 20-21 20-25 21-22 22-23
23-24 24-25
isolated ring systems :
containing 1 : 20 :
```

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 27:CLASS
```

L6 STRUCTURE UPLOADED

=> s 16

SAMPLE SEARCH INITIATED 14:47:47 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 22 TO ITERATE

100.0% PROCESSED

22 ITERATIONS

2 ANSWERS

10572670

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 159 TO 721
PROJECTED ANSWERS: 2 TO 124

L7 2 SEA SSS SAM L6

=> d 16
L6 HAS NO ANSWERS
L6 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 16 sss full
FULL SEARCH INITIATED 14:48:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 446 TO ITERATE

100.0% PROCESSED 446 ITERATIONS 45 ANSWERS
SEARCH TIME: 00.00.01

L8 45 SEA SSS FUL L6

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 180.20 361.41

FILE 'CAPLUS' ENTERED AT 14:48:11 ON 02 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Feb 2008 VOL 148 ISS 6
FILE LAST UPDATED: 1 Feb 2008 (20080201/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 18

10572670

L9 5 L8

=> d 19 1-5 bib abs hitstr

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:410374 CAPLUS

DN 146:402011

TI Process for preparation of 8-amino-3-phenylsulfonylquinolines from 8-fluoro-3-phenylsulfonylquinoline and amines in the presence of base and solvent.

IN Wade, Charles Edward

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 26pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007039238	A1	20070412	WO 2006-EP9460	20060926
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI GB 2005-19758 A 20050928

OS CASREACT 146:402011; MARPAT 146:402011

GI




AB Title compds. [I; R₁, R₂ = H, alkyl; NR₁R₂ = (substituted) 4-7 membered heterocyclyl], were prepared by reaction of 8-fluoro-3-phenylsulfonylquinoline with R₁R₂NH (variables as above) in the presence of base and solvent. Thus, 8-fluoro-3-phenylsulfonylquinoline (preparation given), piperazine, and K₂CO₃ were heated together in n-propanol at 100° for 23 h to give 86% 3-phenylsulfonyl-8-piperazin-1-ylquinoline. Polymorphic forms II and III of the latter were prepared via recrystn.

IT 607742-69-8P, 3-Phenylsulfonyl-8-piperazin-1-ylquinoline

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of aminophenylsulfonylquinolines from fluorophenylsulfonylquinolines and amines in the presence of base and solvent)

RN 607742-69-8 CAPLUS

CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:493996 CAPLUS

DN 145:8187

TI Preparation of isotopomeric piperazine-containing ligands labeling and diagnostic imaging of 5-HT6 receptors

IN Gee, Antony David; Martarello, Laurent; Johnson, Christopher Norbert; Witty, David R.

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006053785	A1	20060526	WO 2005-EP12463	20051117
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	CA 2588381	A1	20060526	CA 2005-2588381	20051117
	EP 1824830	A1	20070829	EP 2005-807786	20051117
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,			

10572670

IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR
PRAI GB 2004-25548 A 20041119
WO 2005-EP12463 W 20051117
OS CASREACT 145:8187; MARPAT 145:8187
GI




AB Piperazine-containing ligands [I; R1 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; R2 = F; or R1 = C1-4 (fluoro)alkyl and R2 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; e.g., (11C-N-methyl)-3-[(3-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)quinoline; 5-HT6 receptor pKi 9.82], which are useful for the labeling and diagnostic imaging of 5-HT6 receptors functionality and the treatment of CNS related disorders, are prepared

IT 607743-50-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(in the preparation of isotopomeric piperazine-containing ligands labeling and diagnostic imaging of 5-HT6 receptors)

RN 607743-50-0 CAPLUS


CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:395276 CAPLUS
 DN 142:430310
 TI Process for the preparation of a crystal polymorphic form of
 3-phenylsulfonyl-8-piperazin-1-ylquinoline
 IN Gladwin, Asa Elisabeth
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 18 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040124	A1	20050506	WO 2004-EP10843	20040923
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004283805	A1	20050506	AU 2004-283805	20040923
	CA 2540022	A1	20050506	CA 2004-2540022	20040923
	EP 1667975	A1	20060614	EP 2004-765655	20040923
	EP 1667975	B1	20071128		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1856471	A	20061101	CN 2004-80027527	20040923
	BR 2004014678	A	20061128	BR 2004-14678	20040923
	JP 2007506702	T	20070322	JP 2006-527373	20040923
	IN 2006DN00970	A	20070817	IN 2006-DN970	20060224
	US 2007032504	A1	20070208	US 2006-572670	20060320
	MX 2006PA03375	A	20060608	MX 2006-PA3375	20060324
	KR 2007020372	A	20070221	KR 2006-705895	20060324
	NO 2006001791	A	20060424	NO 2006-1791	20060424
PRAI	GB 2003-22629	A	20030926		
	WO 2004-EP10843	W	20040923		
OS	CASREACT 142:430310				
AB	Polymorphic crystalline forms of 3-phenylsulfonyl-8-piperazin-1-ylquinoline are synthesized, characterized, and claimed in the treatment of CNS (e.g., schizophrenia) and other disorders.				
IT	607742-69-8P, 3-Phenylsulfonyl-8-piperazin-1-ylquinoline RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (process for the preparation of a crystal polymorphic form of 3-phenylsulfonyl-8-piperazin-1-ylquinoline)				
RN	607742-69-8 CAPLUS				
CN	Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)				




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:260030 CAPLUS
DN 142:336394
TI Preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders
IN Johnson, Christopher Norbert; Witty, David R.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2


DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026125	A1	20050324	WO 2004-EP10129	20040909
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1663980	A1	20060607	EP 2004-765057	20040909
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
	JP 2007505075	T	20070308	JP 2006-525773	20040909
	US 2006287334	A1	20061221	US 2006-571405	20060310
PRAI	GB 2003-21473	A	20030912		
	WO 2004-EP10129	W	20040909		
OS	CASREACT 142:336394; MARPAT 142:336394				
GI					




- AB Title compds. I [R¹ = (un)substituted alkyl, alkylcycloalkyl, alkoxyalkyl, alkyl(hetero)aryl, alkylheterocyclyl; R² = H or alkyl; m = 1-4; when m > 1, two R² groups may be linked to form a CH₂, (CH₂)₂ or (CH₂)₃ group; R³-R⁵ = independently H, halo, CN, CF₃, OCF₃, alkyl, alkoxy, alkanoyl, CONH₂ and derivs.; n = 1 - 3; p = 1-2; and their pharmaceutically acceptable salts] were prepared as 5HT₆ receptor antagonists in treatment of CNS disorders. Thus, condensation of 3-phenylsulfonyl-8-(piperazin-1-yl)quinoline (preparation given) with 4-fluorobenzaldehyde gave II. I were tested and showed good affinity for the 5-HT₆ receptor, having pK_i values ≥ 7.0 at human cloned 5-HT₆ receptors.
- IT 607742-55-2P, 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline hydrochloride 607742-69-8P, 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders)
- RN 607742-55-2 CAPLUS
- CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl

10572670

RN 607742-69-8 CAPLUS
CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:777764 CAPLUS
DN 139:292163
TI Preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of
CNS disorders
IN Ahmed, Mahmood; Johnson, Christopher Norbert; Jones, Martin C.; MacDonald,
Gregor James; Moss, Stephen Frederick; Thompson, Mervyn; Wade, Charles
Edward; Witty, David
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080580	A2	20031002	WO 2003-EP3197	20030325
	WO 2003080580	A3	20040205		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2479786	A1	20031002	CA 2003-2479786	20030325
	AU 2003219103	A1	20031008	AU 2003-219103	20030325
	EP 1497266	A2	20050119	EP 2003-714889	20030325
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003008696	A	20050125	BR 2003-8696	20030325
	CN 1656075	A	20050817	CN 2003-811644	20030325

JP	2005531518	T	20051020	JP	2003-578335	20030325
TW	268928	B	20061221	TW	2003-92106558	20030325
RU	2309154	C2	20071027	RU	2004-131641	20030325
ZA	2004007320	A	20051004	ZA	2004-7320	20040912
IN	2004DN02703	A	20070302	IN	2004-DN2703	20040914
MX	2004PA09318	A	20050125	MX	2004-PA9318	20040924
US	2005124628	A1	20050609	US	2004-509078	20040927
NO	2004004588	A	20041025	NO	2004-4588	20041025
PRAI	GB 2002-7289	A	20020327			
	GB 2002-25678	A	20021104			
	WO 2003-EP3197	W	20030325			
OS	MARPAT 139:292163					
GI						




AB Title compds. I [R1, R2 = H, alkyl; R1R2, R22 = (CH2)2-4; R3-R5 = H, halogen, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, (un)substituted CONH2; A = (un)substituted aryl; m = 1-4; n = 1-3, p = 1, 2] were prepared for use as HT6 receptor antagonists in treatment of CNS disorders. Thus, 8-iodo-3-phenylsulfonylquinoline was prepared from 8-nitroquinoline and was treated with 1-tert.-butoxycarbonylpiperazine, followed by deblocking, to give 3-phenylsulfonyl-8-piperazinoquinoline.

IT 607742-55-2P 607742-69-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)

RN 607742-55-2 CAPLUS


CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI)
 (CA INDEX NAME)

10572670



● HCl

RN 607742-69-8 CAPLUS
CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



IT 607742-56-3P 607742-57-4P 607742-58-5P
607742-59-6P 607742-60-9P 607742-61-0P
607742-62-1P 607742-63-2P 607742-64-3P
607742-65-4P 607742-66-5P 607742-68-7P
607742-71-2P 607742-72-3P 607742-73-4P
607742-74-5P 607742-75-6P 607742-85-8P
607742-86-9P 607742-87-0P 607742-88-1P
607742-89-2P 607742-90-5P 607742-92-7P
607742-93-8P 607742-94-9P 607742-95-0P
607742-96-1P 607742-97-2P 607743-04-4P
607743-46-4P 607743-47-5P 607743-48-6P
607743-49-7P 607743-50-0P 607743-51-1P
607743-52-2P 607743-53-3P 607743-54-4P
607743-55-5P 607743-56-6P 607743-58-8P
607743-60-2P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)

RN 607742-56-3 CAPLUS


10572670

CN Quinoline, 3-[(2-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 607742-57-4 CAPLUS
CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-58-5 CAPLUS
CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)


10572670



● HCl

RN 607742-59-6 CAPLUS

CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 607742-60-9 CAPLUS

CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)


10572670



● HCl

RN 607742-61-0 CAPLUS

CN Quinoline, 3-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 607742-62-1 CAPLUS


CN Quinoline, 8-(1-piperazinyl)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10572670



● HCl


RN 607742-63-2 CAPLUS
CN Quinoline, 7-chloro-3-(phenylsulfonyl)-8-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-64-3 CAPLUS
CN Quinoline, 6-methyl-3-(phenylsulfonyl)-8-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

10572670




● HCl

RN 607742-65-4 CAPLUS

CN Quinoline, 8-[(3R)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 607742-66-5 CAPLUS

CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10572670



● HCl

RN 607742-68-7 CAPLUS
CN Quinoline, 8-[(2S)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)-,
monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 607742-71-2 CAPLUS
CN Quinoline, 3-[(2-methylphenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX
NAME)

10572670




RN 607742-72-3 CAPLUS

CN Quinoline, 3-[(2-methoxyphenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607742-73-4 CAPLUS


CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607742-74-5 CAPLUS


CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)

10572670



RN 607742-75-6 CAPLUS


CN Quinoline, 8-((1-piperazinyl)methyl)-3-((4-fluorophenyl)sulfonyl)- (CA INDEX NAME)



RN 607742-85-8 CAPLUS

CN Quinoline, 3-((2-methylphenyl)sulfonyl)-8-((3S)-3-methyl-1-piperazinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 607742-86-9 CAPLUS

CN Quinoline, 3-((2-methoxyphenyl)sulfonyl)-8-((3S)-3-methyl-1-piperazinyl)- (CA INDEX NAME)

10572670


Absolute stereochemistry.



RN 607742-87-0 CAPLUS

CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 607742-88-1 CAPLUS

CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.


10572670



RN 607742-89-2 CAPLUS

CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 607742-90-5 CAPLUS

CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.


10572670



RN 607742-92-7 CAPLUS

CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 607742-93-8 CAPLUS

CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.


10572670



RN 607742-94-9 CAPLUS

CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-[[2-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607742-95-0 CAPLUS

CN Quinoline, 8-[(2R)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.


10572670



RN 607742-96-1 CAPLUS


CN Quinoline, 8-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-3-(phenylsulfonyl)-,
rel- (CA INDEX NAME)

Relative stereochemistry.



RN 607742-97-2 CAPLUS

CN Quinoline, 8-(3,3-dimethyl-1-piperazinyl)-3-(phenylsulfonyl)- (CA INDEX
NAME)




RN 607743-04-4 CAPLUS

10572670

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[3-(phenylsulfonyl)-8-quinolinyl]-,
monohydrochloride, (1S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 607743-46-4 CAPLUS


CN Quinoline, 3-[(2-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX
NAME)




RN 607743-47-5 CAPLUS

CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX
NAME)


10572670



RN 607743-48-6 CAPLUS
CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX
NAME)




RN 607743-49-7 CAPLUS
CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX
NAME)




RN 607743-50-0 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX
NAME)

10572670




RN 607743-51-1 CAPLUS

CN Quinoline, 3-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-52-2 CAPLUS


CN Quinoline, 8-(1-piperazinyl)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 607743-53-3 CAPLUS


CN Quinoline, 7-chloro-3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)

10572670



RN 607743-54-4 CAPLUS


CN Quinoline, 6-methyl-3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-55-5 CAPLUS

CN Quinoline, 8-[(3R)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 607743-56-6 CAPLUS

CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)


10572670

Absolute stereochemistry.



RN 607743-58-8 CAPLUS
CN Quinoline, 8-[(2S)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 607743-60-2 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[3-(phenylsulfonyl)-8-quinolinyl]-, (1S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

10572670



=> file caold
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
27.73	389.14

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.00	-4.00

CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 14:48:43 ON 02 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 18
L10 0 L8

=> file chemcats
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.46	389.60

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

10572670

CA SUBSCRIBER PRICE	0.00	-4.00
---------------------	------	-------

FILE 'CHEMCATS' ENTERED AT 14:48:52 ON 02 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE LAST UPDATED 26 JANUARY 2008 (20080126/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPB, HELP SPC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ. For the list of current catalogs, enter HELP CTA, HELP CTB, HELP CTC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 20 million records. See HELP CONTENT and NEWS FILE for details.

=> s l8
L11 0 L8

=> log h		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.94	390.54
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-4.00

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:49:04 ON 02 FEB 2008